Physician profile
Yue Wang
NPI 1982838645
$2,768.66
in general payments reported to CMS, 2019-2025
34 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $15.82 · 2021: $252 · 2022: $513 · 2023: $834 · 2024: $409 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $78.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.55 |
| Education | $78.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $337.31 | 2020-2025 | |
| Pfizer INC. | $204.52 | 2019-2024 | |
| Celgene Corporation | $172.32 | 2022-2025 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $169.16 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $164.18 | 2021-2024 | Erleada, Akeega, Rybrevant |
| Gilead Sciences, INC. | $158.39 | 2021-2025 | Trodelvy |
| Amgen INC. | $154.88 | 2019-2022 | |
| Tempus Ai, INC | $153.79 | 2024-2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $121.13 | 2019 | |
| Eisai INC. | $100.61 | 2019-2025 | |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Beigene USA, INC. | $92.10 | 2023 | Brukinsa |
| Astellas Pharma US INC | $89.58 | 2024-2025 | Padcev, Xtandi, Xospata |
| Glaxosmithkline, LLC. | $83.31 | 2023-2025 | Blenrep, Ojjaara |
| Puma Biotechnology, INC. | $78.33 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $65.46 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $52.56 | 2022-2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $48.08 | 2021 | |
| Tactile Systems Technology INC | $39.50 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Morphosys, US INC. | $38.27 | 2022-2023 | Monjuvi |
| Daiichi Sankyo INC. | $36.51 | 2021 | |
| Merck Sharp & Dohme LLC | $35.90 | 2019-2021 | |
| Genmab U.S., INC. | $33.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.23 | 2025 | |
| Adaptive Biotechnologies Corporation | $29.04 | 2023 | Clonoseq |
| Seagen INC. | $26.63 | 2021-2022 | |
| Abbvie INC. | $24.43 | 2024 | |
| Emd Serono, INC. | $23.50 | 2023 | Bavencio |
| Beone Medicines USA, INC. | $20.47 | 2025 | Brukinsa |
| Lilly USA, LLC | $20.13 | 2021 | |
| Davol INC. | $19.41 | 2023 | Arista Ah Flexitip |
| Array Biopharma INC | $19.25 | 2025 | Braftovi, Mektovi, Tukysa |
| Stemline Therapeutics INC. | $17.88 | 2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yue Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.